329 related articles for article (PubMed ID: 23026641)
1. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
[TBL] [Abstract][Full Text] [Related]
2. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
4. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
5. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
[TBL] [Abstract][Full Text] [Related]
6. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
[TBL] [Abstract][Full Text] [Related]
7. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
8. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
[TBL] [Abstract][Full Text] [Related]
9. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation: should we test for it, and does it matter?
Roberts PJ; Stinchcombe TE
J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
[TBL] [Abstract][Full Text] [Related]
11. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
13. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
14. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
[TBL] [Abstract][Full Text] [Related]
15. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
17. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
18. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
[TBL] [Abstract][Full Text] [Related]
19. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
20. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
